CoCo: Long-term Effects of COVID-19: a Comparative Cohort Study

Sponsor
KU Leuven (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05002205
Collaborator
(none)
180
28

Study Details

Study Description

Brief Summary

This study is a longitudinal cohort study which investigates the effect of COVID-19 in ambulatory care. This study aims to assess the effect of COVID-19 beyond the acute phase, i.e. on long-term symptoms, respiratory and cardiovascular health, use of health services, and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaires
  • Other: spirometry
  • Other: ECG
  • Other: 1 minute sit to stand test
  • Other: Vital parameters

Detailed Description

This study is a longitudinal cohort study comparing two cohorts. One cohort tested positive for SARS-CoV-2 and the other tested negative for SARS-CoV-2 matched by the timing of testing in the past 6 months. Participants will be observed for two years after their test for COVID-19 with online surveys at different time intervals and face-to-face follow-up visits.

Study Design

Study Type:
Observational
Anticipated Enrollment :
180 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Long-term Effects of COVID-19: a Comparative Cohort Study
Anticipated Study Start Date :
Aug 31, 2021
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
COVID-19

exposed cohort with a diagnosis of COVID-19 in the last 6 months

Other: Questionnaires
Participants will be followed up by means of online surveys and 2 study visits.

Other: spirometry
During two study visits, the lung function will be measured (FVC, FEV1)

Other: ECG
During two study visits, the presence of arrhythmia will be explored.
Other Names:
  • elecrocardiogram
  • Other: 1 minute sit to stand test
    Physical endurance is tested during 2 study visits.

    Other: Vital parameters
    blood pressure, pulse, weight

    no history of COVID-19

    non-exposed cohort without a diagnosis of COVID-19. Tested for COVID-19 because of symptoms at the same time (+/- 1 month) as the exposed cohort.

    Other: Questionnaires
    Participants will be followed up by means of online surveys and 2 study visits.

    Other: spirometry
    During two study visits, the lung function will be measured (FVC, FEV1)

    Other: ECG
    During two study visits, the presence of arrhythmia will be explored.
    Other Names:
  • elecrocardiogram
  • Other: 1 minute sit to stand test
    Physical endurance is tested during 2 study visits.

    Other: Vital parameters
    blood pressure, pulse, weight

    Outcome Measures

    Primary Outcome Measures

    1. Fatigue severity 6 months after diagnosis of COVID-19. [6 months post-COVID]

      Data for this endpoint are collected with a questionnaire during the first study visit at 6 months. The severity of fatigue will be assessed using the Fatigue Severity Scale (FSS). This is a 9-item scale which measures the severity of fatigue and how it affects a person's activities and lifestyle. The score ranges from 7 to 63, with higher values indicating more fatigue.

    Secondary Outcome Measures

    1. Incidence of post-COVID symptoms [6 months, 9 months, 1 year, 1.5 year and 2 years post-COVID]

      Incidence of each individual symptoms at 6 months, 9 months, 1 year, 1.5 years and 2 years including cough, difficulty breathing, tightness on the chest, pain in the lungs, throatache, muscle ache, muscle weakness, joint pain, pain between the shoulder blades, headache, dizziness, confusion, concentration loss/lack of focus, concentration problems on short and long term, feeling absent, difficulties finding words/afasia, palpitations, hot flushes, sleeping problems, abdominal pain, blurred vision, nerve pains, sensory disorders, mood swings, anxiety, depressive feeling (Source: questionnaire during study visits and remote surveys)

    2. Participants' quality of life [6 months, 9 months, 1 year, 1.5 year and 2 years post-COVID]

      Euroqol EQ-5D-5L: The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate a better outcome (Source: questionnaire during study visits and remote surveys)

    3. Lung function (FEV1, FVC) [6 months and 1 year post-COVID]

      (Source: spirometry during study visits at 6 months and 1 year)

    4. The degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4 (mMRC scale) [6 months, 9 months, 1 year, 1.5 year and 2 years post-COVID]

      0, no breathlessness except on strenuous exercise; 1, shortness of breath when hurrying on the level or walking up a slight hill; 2, walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3, stops for breath after walking ∼100 m or after few minutes on the level; and 4, too breathless to leave the house, or breathless when dressing or undressing

    5. Gustatation [6 months, 9 months, 1 year, 1.5 year and 2 years post-COVID]

      scale from 1 to 10; higher scores indicate more problems with gustation. (Source: questionnaires during study visits and remote surveys)

    6. Olfaction [6 months, 9 months, 1 year, 1.5 year and 2 years post-COVID]

      scale from 1 to 10; higher scores indicate more problems with olfaction. (Source: questionnaires during study visits and remote surveys)

    7. Incidence of diagnoses of COPD [6 months and 1 year post-COVID]

      Source: spirometry during study visits

    8. Exercice capacity and endurance [6 months and 1 year post-COVID]

      Source: 1 minute sit to stand test during study visits

    9. Incidence of cardiovascular events including AMI, lung embolism of stroke [6 months and 1 year post-COVID]

      Questionnaire during study visits

    10. Number of Unplanned hospital admissions of at least 24 hours [within 2 years post-COVID]

      Source: questionnaire during study visits and remote surveys

    11. Number of Visits to healthcare professionals [within 2 years post-COVID]

      Source: questionnaire during study visits and remote surveys

    12. Number of days absent from work [within 2 years post-COVID]

      Source: questionnaire during study visits and remote surveys

    13. Exploring treatments attempted by patients in the scope of post-COVID symptoms [within 2 years post-COVID]

      Categorical options: no treatment; vitamines; antibiotics; puffs; pain medication; anti-inflammatory drugs; others Source: questionnaire during study visits and remote surveys

    14. Exploring the type of counseling patients with post-covid symptoms use. [within 2 years post-COVID]

      Categorical options: no counseling; psychologist; physiotherapist; GP; rehabilitation doctor; other Source: questionnaire during study visits and remote surveys

    15. Exploring the meaning of fatigue post-COVID and its impact on their daily lives [+/- 6 months post-COVID]

      Source: semi-structured interviews online

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Participants eligible for inclusion in this study for the exposed cohort with a diagnosis of COVID-19 in the last 6 months must meet all of the following criteria:

    1. Aged 18 years or older;

    2. Positive result on a rapid Ag test or PCR for SARS-CoV-2 for Covid-19 compatible symptoms a maximum of 6 months before inclusion;

    3. Patient is community-dwelling;

    4. Participant or their proxy is willing and able to give informed consent for participation in this study;

    5. Participant is willing to comply with all study procedures.

    Participants are sampled in the same practices as the exposed cohort and are eligible for inclusion in this study for the non-exposed without a diagnosis of COVID-19 in the last 6 months when they meet all of the following criteria:

    1. Aged 18 years or older;

    2. Tested because of suggestive symptoms with a rapid Ag test or PCR for SARS-CoV-2 at the same time (+/- 1 month) as the exposed cohort, of which the result was negative

    3. Patient is community-dwelling;

    4. Participant or their proxy is willing and able to give informed consent for participation in this study;

    5. Participant is willing to comply with all study procedures.

    Exclusion Criteria:

    Participants eligible for the cohort with COVID-19 in the last 6 months must not meet any of the following criteria:

    1. Patients in palliative care;

    2. Patients for whom there is already someone from the same household participating;

    3. Judgement of the recruiting clinician deems participant ineligible.

    Participants eligible for the cohort without COVID-19 must not meet any of the following criteria:

    1. A positive test for a SARS-CoV-2 infection in the last 2 years;

    2. Patients in palliative care;

    3. Patients for whom there is already someone from the same household participating;

    4. Judgement of the recruiting clinician deems participant ineligible.

    Prior vaccination against Covid-19 is not an exclusion criterion.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • KU Leuven

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ann Van den Bruel, Associate professor, KU Leuven
    ClinicalTrials.gov Identifier:
    NCT05002205
    Other Study ID Numbers:
    • S65768
    First Posted:
    Aug 12, 2021
    Last Update Posted:
    Aug 18, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 18, 2021